Allogeneic hematopoietic SCT (HSCT) has been shown to be an effective treatment option for advanced renal cell cancer (RCC). However, tumor resistance/relapse remains as the main post transplant issue. Therefore, enhancing graft-versus-tumor (GVT) activity without increasing GVHD is critical for improving the outcome of HSCT. We explored the GVT effect of haploidentical-SCT (haplo-SCT) against RCC in murine models. Lethally irradiated CB6F1 ( ) successfully provided GVT activity without incurring GVHD. This effect elicited murine RCC growth control and consequently displayed a comparative survival advantage of haplo-SCT recipients when compared with MHC-matched (B6D2F1-CB6F1) and parent-F1 (B6-CB6F1) transplant recipients. Recipients of haplo-SCT had an increase in donor-derived splenic T-cell numbers, T-cell proliferation and IFN-g-secreting donor-derived T-cells, a critical aspect for anti-tumor activity. The splenocytes from B6CBAF1 mice had a higher cytotoxicity against RENCA cells than the splenocytes from B6 and B6D2F1 donors after tumor challenge. These findings suggest that haplo-SCT might be an innovative immunotherapeutic platform for solid tumors, particularly for renal cell carcinoma.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) has been successfully used for treatment of hematological malignancies. However, this approach has not been used for patients with solid tumors, even for tumor types where immune modulatory treatments are widely used. Anti-tumor or graft-versus-tumor (GVT) effects of the graft contribute to the elimination of the residual tumor cells in certain types of malignancies. For the most part, the transplant community does not consider patients with solid tumors to be good candidates for allogeneic HSCT due to transplant-related mortality and late reconstitution of immune competency. However, pioneering studies suggest that non-myeloablative allogeneic HSCT for advanced renal cell cancer (RCC) might induce sustained regression of metastatic RCC in patients who have failed conventional therapies. [1] [2] [3] [4] [5] Seventy-four patients with advanced RCC underwent allogeneic HSCT following non-myeloablative conditioning, and 39% of the patients were responsive, including 9.5% of patients that underwent a CR. 5 The median tumor response occurred at 133 days after allogeneic HSCT and there were detectable RCC-reactive CD8 T-cells in responsive patients. 5 The onset of RCC regression after non-myeloablative HSCT is delayed by several months, which suggests that GVT activity of MHC-matched HSCT is a slow process and may not be sufficient to control aggressive disease. In a European study, OS was found to be 30% at 2 years after HSCT. 3 However, CALGB data did not support these observations and did not report any objective responses after allogeneic HSCT in patients with advanced RCC. 6 Finally, in a recent report, Bregni and co-workers 7 observed a 5-year survival rate for 20% of 25 patients with metastatic RCC who had reduced intensity conditioning for allogeneic HSCT from HLA-compatible sibling donors.
Early disease progression after transplant has been strongly associated with treatment failure and short survival. 3, 5, 7 Addressing a strategy to control disease early after allogeneic HSCT might improve the survival of the patients with RCC. Haploidentical-SCT (haplo-SCT) could provide an enhanced allogeneic T-cell and natural killer (NK)-cell response and augment GVT effect due to the MHC molecule disparity. Vanclee et al. 8 showed in murine breast cancer model that haplo-SCT could successfully induce anti-tumor activity and provide a survival advantage compared with syngeneic transplant. Non-myeloablative haplo-HSCT was reported to induce anti-tumor activity in one patient with advanced RCC after successful engraftment, but the patient eventually developed progression of the disease 1 year after transplant. 9 Pé rez-Martínez et al. 10, 11 reported that three patients with pediatric metastatic solid tumors were transplanted with mobilized T-cell-depleted (TCD) peripheral stem cells from haploidentical donors. One patient with mismatched killer immunglobulin like receptors (KIR)-HLA achieved CR and was alive 21 months after transplant at time of the report, suggesting that KIR-HLA receptor-ligand mismatch could induce GVT activity after haplo-SCT. Another study also suggests the feasibility of using haplo-SCT in the pediatric population with advanced neuroblastomas/sarcomas. 12 However, the utility of haploidentical HSCT for the treatment of RCC have not been yet evaluated in the clinical studies. Here, we report the efficacy of haplo-SCT in RCC-bearing recipients in murine models. Murine RCC is a well-known solid tumor model. We have previously established two allo-SCT models with murine RCC (RENCA), and demonstrated that adding low numbers of selected donor CD8 þ T-cells to the allograft can mediate GVT activity against murine RCC, without inducing lethal GVHD. This GVT activity was dependent on IFN-g and FasL expression on CD8 þ T-cells. 13 The data suggest that CD8 þ T-cells produce IFN-g, which upregulates Fas on RENCA cells. This Fas expression on RENCA cells facilitates tumor elimination from the host via Fas ligand-expressing allo-activated CD8 þ T-cells.
In this study, we used a clinically relevant haploidentical transplant model; B6CBAF1-CB6F1, in which both donor and recipient shared the same MHC haplotype (H2Kb). We show that enhancing GVT activity in the early period of HSCT without increasing GVHD is the critical step for improving the outcome of haplo-SCT in RCC-bearing recipients. 
MATERIAL AND METHODS Mice

Cell preparations
Single-cell suspensions were obtained from spleen and BM according to standard protocols. Harvest medium consisted of RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin, 100 mg/mL streptomycin and 2 mM L-glutamine. For TCD, BM cells were incubated with anti-Thy 1. Cell lines RENCA, murine kidney carcinoma cell line, retrovirally transduced to express a triple fusion protein consisting of HSV thymidine kinase, enhanced green fluorescent protein and firefly luciferase (TGL) (kindly provided by Dr Marcel van den Brink, Memorial Sloan Kettering Cancer Center, New York, NY, USA) was maintained in cell culture medium consisted of RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin, 100 mg/mL streptomycin, 1 mM non-essential amino acids, 10 mM sodium pyruvate and 2 mM L-glutamine. Mouse lymphoma cell lines were used for cytotoxicity assays; C1498 was also maintained in complete RPMI 1640 media supplemented with 10% heat-inactivated fetal bovine serum, 100 IU/mL penicillin, 100 mg/ mL streptomycin and 2 mM L-glutamine. Cells were maintained at 37 1C in a humidified atmosphere containing 5% CO 2 .
BMT and monitoring the mice HSCT experiment consisted of split-dose lethal irradiation on day 0 followed by i.v. injection of TCD BM cells from donors. Female donors were between 8 and 12 weeks of age and female recipients were between 10 and 12 weeks of age.
GVHD scoring and tumor growth assessment with in vivo bioluminescence
Recipients of HSCT were monitored for 4 months to determine the effect of the specific transplant model on survival. Recipients were monitored daily for survival and weekly for GVHD morbidity. A semi-quantitative GVHD scoring system developed by Dr Ferrara and coworkers 14 was used for weekly GVHD evaluation. Ear-tagged animals were individually scored every week for five clinical parameters on a scale from 0 to 2: weight loss, posture, mobility, fur and skin. A clinical GVHD index was generated by summation of the five criteria scores (0-10).
In GVT experiments, bioluminescent signal intensity of tumor-bearing mice was determined weekly. Ten minutes after i.p. injection of 3.75 mg/mouse D-Luciferin (Xenogen; Alameda, CA, USA), mice were anaesthetized and placed into the light tight chamber of the IVIS-200 Optical Imaging system (Xenogen; San Francisco, CA, USA). Gray-scale photographic images of the mice were acquired first and then a low-level bioluminescent signal was recorded. Pseudo-color images showing the whole-body distribution of bioluminescent signal intensity were superimposed on the gray-scale photographs and total flux (photons/s) was determined for individual mice. The cause of death was confirmed by necropsy and histopathology.
Reagents and antibodies
Anti-murine CD16/CD32 FcR block (2.4G2) and all of the following fluorochrome-labeled Abs against murine Ags were obtained from BD Biosciences (San Diego, CA, USA): CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), CD45R/B220 (RA3-6B2), NK1.1 (PK136), anti-IFN-g (XMG1.2), anti-TNF-a (MP6-XT22) and isotype controls; rat IgG2a-k (R35-95), rat IgG2a-k (B39-4), rat IgG2b-k (A95-1), rat IgG1-k (R3-34), hamster IgG1-k (A19-3), hamster IgG1-l (Ha4/8), conjugated streptavidin/PerCP, and conjugated streptavidin/APC.
Flow cytometric analysis
Cells were stained with specific Abs and acquired via flow cytometer Cytotoxicity with 51 Chromium release assay B6, B6CBA and B6D2 mice, were injected i.p. with 1 Â 10 6 RENCA-TGL cells and spleens were collected on day 3. 15 Target cells, RENCA-TGL and C1498, were labeled with 100 mCi 51 Cr for 1 h, and then after three washes were plated in U-bottom plates at 10 4 cells/well concentration (Costar, Corning, NY, USA). Splenic T-cells were added at various effector to target ratios, that is, 40:1, 20:1, 10:1, in a final volume of 200 mL and incubated for 18 h at 37 1C and 5% CO 2 . Subsequently, 35 mL of supernatant was removed from each well and counted in a gamma counter (Wallac 1450 Microbeta Plus, PerkinElmer) to determine experimental release. Spontaneous release was obtained from wells that contained only target cells, and total release was obtained from wells treated with 10% Triton X-100. The spontaneous release was o15% of the total release. Percent cytotoxicity was calculated by the following formula: percent cytotoxicity ¼ 100 Â (experimental release À spontaneous release)/(total release À spontaneous release).
Statistics
Mean values and s.e.m. were calculated with GraphPad Prism 4.0 (GraphPad Software, Inc., La Jolla, CA, USA), and statistical comparisons, including nonparametric Mann-Whitney U-test and survival analysis with log-rank test are all performed with GraphPad Prism. (Figures 1a and b) . Both groups had more than 90% donor cell engraftment in the spleen and BM (Figures 1c  and d ).
RESULTS
Haploidentical BM cells engraft well without signs of GVHD
GVT and GVHD after haplo-SCT Previously, an allogeneic HSCT model using RENCA cells that express a triple fusion protein (TGL) was established, which allowed multimodality in vivo imaging. 13 All animals (CB6F1) that had i.v. injection of 2 Â 10 5 RENCA-TGL cells, accepted tumor within 2 weeks, and succumbed to tumor growth within 6 weeks (Figure 2a) . When CB6F1 mice were transplanted with B6 or B6CBA TCD BM cells (without T-cell infusion) and infused with 2 Â 10 5 RENCA-TGL cells, the median survivals were 28.4 and 38 days, respectively (data not shown). An optimal T-cell dose for generating GVT effects without GVHD was determined for the haplo-SCT model. B6CBAF1 TCD BM was transplanted to lethally irradiated CB6F1 mice with and without T-cells. We used two different T-cell doses and compared with control group, which received only BM cells without T-cells. Further, 1 Â 10 5 haploidentical T-cells provided sufficient GVT activity and resulted in significantly improved survival (Figure 2a) . We used this T-cell dose in the following experiments.
We tested the requirement of CD8 þ T-cells on GVT in the haplo-SCT model. Similar transplant experiments were repeated, and animals were injected with no T-cells, pan T-cells, CD4 þ T-cells or CD8 þ T-cells. Haploidentical CD8 þ T-cells provided a better antitumor activity than CD4 þ T-cells, while unseparated T-cells resulted in significantly improved survival than either subset alone (Figure 2b ). This demonstrates that GVT activity against RENCA tumor is mainly driven by CD8 þ T-cells but is optimized in the presence of CD4 þ T-cells.
When tumor development was monitored with bioluminescence imaging (BLI), the recipients of haplo-SCT BM and T-cells did not reveal any tumor development for the first 50 days (Figure 2c ), and had a significantly improved survival compared with other groups (Figure 2d ).
We increased the dose of T-cells to 5 Â 10 5 , and monitored RENCA-TGL growth with BLI (Figure 3a) . Long-term survival reached around 70% for animals transplanted with haploidentical TCD BM (Figure 3b ). Animals that had either matched allogeneic (B6D2F1 donor) or parent-F1 (B6 donor) HSCT had increased survival with higher dose T-cell infusion, but there were also signs of GVHD. However, only one animal transplanted from B6 donor was lost with GVHD, all other deaths were tumor associated. Weight loss was more prominent for the haploidentical and parent-F1 donor-transplanted mice compared with those matched allogeneic donor-transplanted mice. However, recovery in the haplo-SCT group was substantially more rapid (Figure 3c ).
Haploidentical T-cell infusion provides better T-and NK-cell reconstitution
Recipients of haplo-SCT were killed at day 28 after transplant and immune reconstitution was evaluated and compared with the parent-F1 donor recipients. Donor-derived splenic T-and NK-cells were statistically higher in recipients of haplo-SCT (Figure 4a ). Splenocytes obtained from the haplo-SCT donor recipients had a significantly higher Con A stimulation index than those splenocytes retrieved from comparable B6 donor recipients (Figure 4b ).
Fourteen days after transplant, we then explored T-cell number and activity in recipients of haplo-SCT with low-dose (1 Â 10 5 ) donor T-cell infusion. Again, splenic CD4 þ and CD8 þ T-cells were found to be higher in haplo-SCT-transplanted groups (Figure 4c ), including higher intracellular IFN-g expression (Figure 4d ). These data suggested that early T-cell activity of the haploidentical T-cells might explain the prominent GVT effect we observed in RENCA-TGL-bearing mice.
We then compared T-cell cytotoxic activity of donor T-cells against RENCA-TGL cells. Untransplanted donor mice were challenged with 1 Â 10 6 RENCA-TGL cells injected i.p. 15 In a preliminary experiment, we challenged six mice from each strain and euthanized half of them, 3 days after tumor challenge and the final three mice 10 days after tumor challenge. It has been previously reported that RENCA-specific cell kill is highest at 3 days after RENCA injection. 15 We observed maximum cytotoxicity 3 days after the tumor challenge, and when animals were euthanized 10 days after the tumor challenge, there were no difference among strains in terms of cytotoxicity against RENCA-TGL cells (data not shown). We repeated this experiment and challenged six animals per group with RENCA-TGL cells. Mice were euthanized 3 days after tumor challenge and single-cell suspensions of splenocytes were obtained. Cytotoxicity of splenocytes was evaluated by 51 Cr release assay. We mimicked the previously published model and evaluated cytotoxicity after incubating splenocytes with target cells for both 6 and 18 h. There was no significant cytotoxicity after 6 h incubation (data not shown), which confirmed the previously published observation that T-cell lysis of the murine RCC (RENCA) was associated via Fas triggering. 16 After 18 h incubation, the splenocytes from B6CBAF1 mice had higher cytotoxicity against RENCA-TGL cells than the splenocytes from B6 and B6D2F1 donors. None of the donors had significant cytotoxicity against C1498 cells, which were used as a non-specific H2K b target (Figure 4e ).
DISCUSSION
We established a murine haploidentical HSCT model and assessed the efficacy of haplo-SCT in animals bearing RCC. Haplo-SCT is an innovative idea for RCC treatment, which has never been studied even in murine models. In this study, we have demonstrated that the haplo-SCT provides a better GVT effect than MHC-matched and parent-F1 allogeneic HSCT without increasing the risk of GVHD. Increased anti-tumor activity might be related to increased T-cell numbers and function in the periphery, including IFN-g secretion and cytotoxic activity of T-cells. We have previously shown that GVT activity towards RENCA is dependent of IFN-g secretion by T-cells. IFN-g upregulates Fas expression on RENCA cells, which induces their elimination by Fas ligand-expressing CD8 þ T-cells. 13 It is also possible that NK cells may have a role in anti-tumor activity in RENCA-bearing mice. 17, 18 Post transplant CY infusion enhanced tolerization of T-cells, which resulted in a reduced risk of GVHD while preserving GVT effect to RENCA cells in murine models. 19, 20 Interestingly, achieving high level of chimerism is not required to develop anti-tumor activity after SCT. 20 Post transplant CY has been successfully used for tolerization in clinical haplo-SCT. 21 Therefore, this method would be easily transferred to the clinic with haplo-SCT for the treatment of RCC.
NK cells have a critical role in the development of GVT activity after haplo-SCT. Activation of NK cells after haploidentical transplantation is well described by missing-self, KIRmismatched or activation of NKG2D/NKG2DL. 10, 11, 22, 23 We have Currently available treatment options for advanced RCC, that is, tyrosine kinase inhibitors (TKI) or mammalian target of rapamycin (mTOR) inhibitors, tackle disease stabilization without a curative intent. 25, 26 In our model, carefully titrated T-cell infusions provided tumor-free survival without GVHD for more than 50% of the animals. High transplant-related mortality has limited to use of allogeneic HSCT for patients with RCC. However, reduced intensity conditioning regimens and GVHD prophylaxis have made transplant a reasonable option for these patients. 4, 5 Considering that relatively toxic high-dose IL-2 administration is the only available curative treatment option for RCC, and durable remission for the patients who received IL-2 treatment is less than 10%, we should start to change our bias against allogeneic HSCT. Allogeneic HSC transplant has been reported to induce durable disease response for about 15-20% of the patients for 5 years, 5, 7 and now we have more tools to augment immune-mediated RCC elimination with haplo-SCT.
Although our murine RCC model may not be fully comparable to human clinical conditions, murine and human GVT activity share similar pathways, and there has been non-myeloablative clinical transplant experience that suggests durable allogeneic HSCT-induced tumor regression in patients with RCC. We believe that a haploidentical HSCT approach will support earlier T-cell activity of haploidentical donor T-cells. Newly active T-cells generated from haplo-SCT suggest a more prominent GVT effect, as observed in RENCA-bearing mice. Consequently, such an approach gives us an opportunity to develop new treatment strategies for patients with TKI and mTOR inhibitor resistant RCC. These studies open a new perspective in the use of SCT as a platform for immunotherapy against solid tumors, including donor leukocyte infusion and vaccination. Pedrazzoli et al. 27 recently reviewed the role of adoptive immunotherapy including allo-SCT in the treatment of solid tumors. Novel tumor-specific modalities that may increase the efficacy of adoptive immunotherapy include harnessing the therapeutic potential of T-cells, transduced with TCRs directed against shared tumor Ags. 27 Interestingly, the combination adoptive immunotherapy with other modalities such as mTOR inhibitors could increase the efficacy of the therapy in patients with advanced RCC. [28] [29] [30] However, there will be a higher GVHD risk after donor leukocyte infusion infusion in haploidentical setting and may not result in increased GVL activity as shown in some experimental models. 31 We conclude that problems including organ toxicity, GVHD, graft manipulation to introduce haplo-SCT to the clinic for RCC can be evaluated with well-designed clinical trials. The collaboration with SCT team and primary oncologists would be a critical step to develop new treatment strategies including SCT for patients with advanced RCC. (e) Cytotoxicity against RENCA-TGL was substantially prominent 3 days after in vivo tumor challenge in B6CBAF1 strain (*Po0.05), and there were less than 5% non-specific cytotoxicity against C1498 cell line at any given E:T ratio. (n ¼ 6 for all groups).
